Cardiovascular Complications in Chronic Kidney Disease

Chronic kidney disease (CKD) is associated with a markedly elevated risk of cardiovascular morbidity and mortality. Progressive loss of renal function leads to a milieu of metabolic disturbances, including uraemic toxin accumulation, chronic inflammation and dysregulated mineral metabolism, which collectively drive endothelial dysfunction, accelerated atherosclerosis and vascular calcification. Structural changes within the myocardium, notably left ventricular hypertrophy and fibrosis, are promoted by pressure overload, fluid retention and altered endocrine signalling factors such as fibroblast growth factor 23. In parallel, disturbances in calcium–phosphate balance foster calcific deposition within the intima and media of arterial walls, reducing vessel compliance and predisposing to ischaemic events. Traditional risk factors—hypertension, diabetes and dyslipidaemia—are compounded by CKD-specific processes, rendering standard preventive strategies less effective. Moreover, interventions such as dialysis and transplantation further modulate cardiovascular risk through haemodynamic stress and immunosuppression. Taken together, these interwoven mechanisms underpin the exceptionally high incidence of myocardial infarction, stroke and heart failure across all stages of CKD, underscoring the global importance of integrated renal–cardiac care pathways.

Research from Nature Portfolio

Recent studies have elucidated the molecular interplay between mineral metabolism and cardiac remodelling in CKD. Work on endocrine factors demonstrates that excessive fibroblast growth factor 23 promotes pathological myocardial hypertrophy by activating intracellular signalling cascades independently of blood pressure changes. Complementary research has dissected the role of circulating uraemic toxins in endothelial injury, identifying specific pathways by which protein-bound solutes impair nitric oxide bioavailability and precipitate vascular stiffening. Advances in single-cell transcriptomics have further characterised the phenotypic shift in vascular smooth muscle cells toward an osteogenic lineage, revealing novel targets to inhibit calcification in uraemic environments.

Cardiovascular Complications in Chronic Kidney Disease publication trend

The graph below shows the total number of articles in cardiovascular complications in chronic kidney disease across all publications each year (not limited to Nature Index journals).

Technical terms

Chronic kidney disease (CKD): Progressive reduction in glomerular filtration rate and/or kidney damage persisting for more than three months.

Estimated glomerular filtration rate (eGFR): Laboratory-derived calculation of kidney filtration capacity based on serum creatinine and demographic factors.

Left ventricular hypertrophy (LVH): Thickening of the heart’s left ventricular wall in response to pressure or volume overload.

Endothelial dysfunction: Impaired vasodilatory and antithrombotic functions of the vascular endothelium, promoting atherosclerosis.

Vascular calcification: Deposition of calcium phosphate crystals within arterial walls, reducing elasticity and increasing cardiovascular risk.

Uraemic toxins: Metabolites normally excreted by the kidneys that accumulate in CKD and exert deleterious systemic effects.

References

1. Kidney replacement therapy: trends in incidence, treatment, and outcomes of myocardial infarction and stroke in a nationwide Scottish study. European Heart Journal (2024).
2. Acute Coronary Syndromes in Chronic Kidney Disease: Clinical and Therapeutic Characteristics. Medicina (2020).
3. Study of Cardiovascular Outcomes in Renal Transplantation: A Prospective, Multicenter Study to Determine the Incidence of Cardiovascular Events in Renal Transplant Recipients in Ontario, Canada. Canadian Journal of Kidney Health and Disease (2017).